Latest 8-K filings

Neurogene Inc. announced positive second quarter 2026 financial results, highlighting significant advancements in its NGN-401 program for Rett syndrome, including compelling clinical data and an extended cash runway.

Ambiq Micro announced record quarterly net sales up 90% year-over-year for Q2 2026, driven by strong demand for its ultra-low-power semiconductor solutions for edge AI.

Incannex Healthcare Inc. announced the receipt of a final A$5.1 million R&D tax incentive refund, bringing the total non-dilutive capital received in 2026 to over A$11.2 million, significantly bolstering its financial flexibility.

Tango Therapeutics announced strong Phase 1/2 data for vopimetostat in pancreatic cancer, positioning it for Phase 3 development, and reported a cash position of $1.0 billion as of June 30, 2026.

Superior Group of Companies, Inc. has amended and restated its credit facilities, increasing capacity to $200 million with a maturity extension to August 2031.

CalciMedica reported Q2 2026 results, announcing a $49 million private placement to advance its pulmonary hypertension program and providing updates on its Auxora and CM5480 candidates.

C4 Therapeutics announced second quarter 2026 financial results, highlighting progress in its cemsidomide clinical trials and a strong cash runway extending to the end of 2028.

Vireo Growth Inc. announced robust second-quarter 2026 financial results, showcasing substantial year-over-year revenue growth fueled by strategic acquisitions and detailing plans for further expansion.

Hemab Therapeutics announced strong Q2 2026 results with significant pipeline progress, including new data for HMB-002 and HMB-003, and advancement of sutacimig towards Phase 3 trials, bolstered by a substantial cash position post-IPO.

CVRx, Inc. announced the departure of its Chief Revenue Officer, Robert John, and the appointment of Paul Verrastro as Interim Head of Sales.

Beyond Meat has announced a 1-for-30 reverse stock split, effective August 13, 2026, to regain compliance with Nasdaq's minimum bid price requirement.

Immunic, Inc. announced the appointment of Elena Ridloff to its Board of Directors and provided an update on its Phase 3 trials for vidofludimus calcium in multiple sclerosis, with top-line data expected by year-end.

DPC Holdings PLC announced record second quarter 2026 revenue of $269 million, up 34% year-over-year, and initiated full-year guidance.

Xtant Medical Holdings, Inc. announced its second quarter 2026 financial results, reporting a significant decrease in revenue and a net loss, attributed to asset sales and changes in reimbursement.

Aura Biosciences announced Q2 2026 results, a strategic shift to ocular oncology, workforce reduction, and key leadership appointments, extending cash runway to 1H 2029.

908 Devices Inc. announced second quarter 2026 financial results, reporting a 23% year-over-year revenue increase and narrowing its Adjusted EBITDA loss, while also raising its full-year revenue guidance.

Upstream Bio reported second quarter 2026 financial results and business updates, highlighting progress in its verekitug development for severe inflammatory respiratory diseases and a cash runway through 2027.

Vestis Corporation reported third quarter 2026 results, showing improved Adjusted EBITDA and Free Cash Flow, leading to an increased full-year outlook.

Chicago Atlantic Real Estate Finance announced its second quarter 2026 financial results, highlighting $59.2 million in gross originations and continued progress on its merger with Chicago Atlantic BDC, Inc.

The Middleby Corporation announced robust second quarter 2026 results, exceeding guidance for revenue and Adjusted EBITDA, completing its Food Processing business spin-off, and raising its full-year 2026 outlook.

Twenty One Capital's CEO, Raphael Zagury, issued a shareholder letter detailing a five-point strategic plan focused on building operating businesses, capital markets capabilities, and a lending business around its significant Bitcoin holdings.

Harvard Bioscience (HBIO) presented an investor overview highlighting strategic debt refinancing, new executive leadership, and a focused strategy on translational science tools, aiming for enhanced financial flexibility and long-term growth.

Broadwind, Inc. announced robust second quarter 2026 financial results, showcasing significant revenue growth and improved profitability driven by a strategic focus on power generation and critical infrastructure markets.

Harvard Bioscience announced second quarter 2026 financial results, reporting an 11% year-over-year revenue increase to $22.7 million and raising its full-year revenue guidance.

Janus International Group announced Q2 2026 financial results, with revenues up 2.4% year-over-year to $233.5 million, but Adjusted EBITDA decreased 18.0% to $40.2 million.

IES Holdings, Inc. announced a definitive agreement to acquire DBM Global Inc., a major structural steel fabricator, for approximately $650 million in cash and stock.

Bioxytran announced encouraging clinical observations in the first patient treated with PLICID, a novel galectin antagonist for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), showing functional improvements without adverse events.

BioXcel Therapeutics has amended its credit agreement, extending the deadline for a material transaction to August 21, 2026, and lowering its minimum liquidity requirement.

Cardinal Infrastructure Group Inc. announced record second quarter 2026 revenue of $226.9 million, an 114% year-over-year increase, and the acquisition of Allied Paving for approximately $120 million.

Green Thumb Industries Inc. announces an amendment to agreements with RYTHM, Inc. that will result in the consolidation of RYTHM into Green Thumb's financial statements starting October 10, 2026.